Indobufen
- Generic Name
- Indobufen
- Drug Type
- Small Molecule
- Chemical Formula
- C18H17NO3
- CAS Number
- 63610-08-2
- Unique Ingredient Identifier
- 6T9949G4LZ
- Background
Indobufen has been used in trials studying the supportive care and prevention of Atrial Fibrillation.
- Indication
用于动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成。也可用于血液透析时预防血栓形成。
- Associated Conditions
- Platelet Aggregation
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Phase 4
Not yet recruiting
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 2846
- Registration Number
- NCT06451198
A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
Phase 4
- Conditions
- Coronary Atherosclerosis
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2022-01-19
- Target Recruit Count
- 60
- Registration Number
- NCT05105750
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease
Not Applicable
Withdrawn
- Conditions
- Stable Coronary Heart Disease
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Target Recruit Count
- 594
- Registration Number
- NCT04308551
GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy
Phase 4
- Conditions
- Coronary Artery DiseaseGastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT04129008
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 5438
- Registration Number
- NCT03871517
- Locations
- 🇨🇳
Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, China
the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
Phase 4
- Conditions
- Coronary Atherosclerosis
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2017-07-31
- Target Recruit Count
- 210
- Registration Number
- NCT03230851
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2010-11-10
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT01232023
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Pusan, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1372
- Registration Number
- NCT00244426
- Locations
- 🇮🇹
Pfizer Investigational Site, Viterbo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath